Any company that’s been looking at the amount of product testing required by the Food and Drug Administration (FDA) for Premarket Tobacco Applications (PMTA) will understand just how extensive and expensive this can be.
At Nerudia, we have used our extensive experience in the vaping and pharmaceutical industries to develop a Bridging Strategy aimed at both meeting the FDA’s mandate of reviewing product applications based upon the protection of public health, whilst attempting to reduce the amount and cost of testing, particularly where companies sell multiple flavours, nicotine strengths and devices. All of which are fully justified and supported by scientific evidence, and a significant balance of primary research.
This Bridging Strategy has taken around six months of intensive development and is now adding value to many of our client’s PMTA development whilst having a significant impact on the overall testing costs.
For more information on how we can help you with PMTA contact us.